Pharmaxis Completes Recruitment of CF Clinical Trial for US
Filed with ASX · · 2 pages · English
Earlier from Syntara
- Appendix 4C - quarterly March 2016
- US FDA Accepts Bronchitol New Drug Application for Review
- Quarterly Share Update - December 2015
- Bronchitol Paediatric CF Trial Reports Postive Results
Later from Syntara
- Pharmaxis Announces Russian Approval for Bronchitol
- S&P DJ Indicies Announces March Quarterly Rebalance
- Research Collaboration with Woolcock Institute
- Chairmans Address to Shareholders
- Synairgen Collaboration Progress
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara